Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Mortality attributable to Plasmodium vivaxmalaria: a clinical audit from Papua, Indonesia

  • Nicholas M Douglas1, 2,
  • Gysje J Pontororing3,
  • Daniel A Lampah3,
  • Tsin W Yeo1,
  • Enny Kenangalem3, 4,
  • Jeanne Rini Poespoprodjo3, 4, 5,
  • Anna P Ralph1, 6,
  • Michael J Bangs7, 8,
  • Paulus Sugiarto9,
  • Nicholas M Anstey1, 6 and
  • Ric N Price1, 2Email author
BMC Medicine201412:217

https://doi.org/10.1186/s12916-014-0217-z

Received: 20 August 2014

Accepted: 22 October 2014

Published: 18 November 2014

Abstract

Background

Plasmodium vivax causes almost half of all malaria cases in Asia and is recognised as a significant cause of morbidity. In recent years it has been associated with severe and fatal disease. The extent to which P. vivax contributes to death is not known.

Methods

To define the epidemiology of mortality attributable to vivax malaria in southern Papua, Indonesia, a retrospective clinical records-based audit was conducted of all deaths in patients with vivax malaria at a tertiary referral hospital.

Results

Between January 2004 and September 2009, hospital surveillance identified 3,495 inpatients with P. vivax monoinfection and 65 (1.9%) patients who subsequently died. Charts for 54 of these 65 patients could be reviewed, 40 (74%) of whom had pure P. vivax infections on cross-checking. Using pre-defined conservative criteria, vivax malaria was the primary cause of death in 6 cases, a major contributor in 17 cases and a minor contributor in a further 13 cases. Extreme anaemia was the most common primary cause of death. Malnutrition, sepsis with respiratory and gastrointestinal manifestations, and chronic diseases were the commonest attributed causes of death for patients in the latter two categories. There were an estimated 293,763 cases of pure P. vivax infection in the community during the study period giving an overall minimum case fatality of 0.12 per 1,000 infections. The corresponding case fatality in hospitalised patients was 10.3 per 1,000 infections.

Conclusions

Although uncommonly directly fatal, vivax malaria is an important indirect cause of death in southern Papua in patients with malnutrition, sepsis syndrome and chronic diseases, including HIV infection.

Keywords

Plasmodium vivax Malaria Mortality Indonesia Papua

Background

Almost three billion people are estimated to be at risk of Plasmodium vivax malaria, the vast majority of whom live in south and southeast Asian countries [1],[2]. In endemic regions, this relapsing disease is responsible for substantial morbidity, mostly associated with recurrent bouts of fever, anaemia [3] and adverse pregnancy outcomes [4],[5]. Plasmodium vivax is not generally regarded as sufficiently virulent to cause death. Notwithstanding this benign reputation, over the last two to three decades, there have been multiple case studies of fatal vivax malaria [6],[7]. More recently, hospital and outpatient surveillance systems have shown that P. vivax-associated mortality may be occurring with greater frequency than previously thought or reported [8]-[11].

In Papua, Indonesia, P. vivax infections exact a considerable toll [8],[10]. This reflects the high risk of multiple recurrences, the presence of high-grade chloroquine-resistance [12], comparatively high-level endemicity [13] and a large proportion of relatively non-immune migrants in the area [14]. The fatality of hospitalised patients with P. vivax parasitaemia in Timika, southern Papua, has been estimated to be similar to that of patients with P. falciparum infections (1.6% versus 2.2% respectively) [10]. In the present study we aimed to determine the extent to which P. vivax contributed to those deaths by conducting an audit of the clinical records of all patients with pure P. vivax infections who died at Mitra Masyarakat Hospital between January 2004 and September 2009.

Methods

Study site

The geography, climate and demographics of Mimika District and its capital city, Timika, have been described elsewhere [4],[10]. Our study was based at the Mitra Masyarakat Hospital (Rumah Sakit Mitra Masyarakat, RSMM), which, until November 2008, was the only referral hospital in the south of Papua. This facility provides treatment to all patients – free of charge for indigenous Papuan residents and at a nominal cost for non-Papuans. The hospital has 101 beds, a 24-hour emergency department, an active outpatient ‘polyclinic’, and a high care unit with facilities for intravenous infusions but not mechanical ventilation. Radiological services include X-ray and ultrasonography. Laboratory facilities are also available for haematologic and biochemical analysis and basic microscopy, but not for microbiological culture. In addition to the hospital, there is also a network of primary health clinics distributed throughout the community. An established community surveillance network covers 14 of these clinics and collects data on the total number of blood smear examinations and the number of malaria positive films read on a weekly basis.

Malaria transmission in Mimika District is generally restricted to lowland areas below 1,500 m elevation where it is associated with efficient mosquito vectors, primarily the Punctulatus group. The estimated average annual incidence of clinical and asymptomatic malaria is 876 episodes per 1,000 people, 46% due to P. falciparum and 39% due to P. vivax [13]. The point prevalence of asexual parasitaemia in the community has been estimated at 16.3% (7.7% for P. falciparum and 6.4% for P. vivax) [13]. Prior to March 2006, hospital guidelines recommended oral quinine plus a 14-day regimen of primaquine for the treatment of patients with uncomplicated vivax malaria. After 2006, quinine was switched to dihydroartemisinin-piperaquine (DHP) for all malaria species. Severe malaria was treated with intravenous quinine prior to May 2005 and intravenous artesunate thereafter.

Prospective hospital surveillance procedures

The methods of malariometric surveillance at RSMM hospital have been described elsewhere [10]. Hospital guidelines dictate that all inpatients should have blood taken for malaria microscopy at the hospital laboratory. In a minority of cases, blood smears are also read by local expert research-based microscopists. Slides are declared negative after review of a minimum of 100 high-power microscope fields and if parasitaemia is present the density is scored semiquantitatively as 1+ to 4+. In 2004, a random sample of 1,083 positive slides from the hospital laboratory was re-examined by an independent expert microscopist with more than 10 years of experience. The overall concordance between initial and subsequent readings was 90% (979/1083). In 1.7% (18/1,083) of the slides, the second reading was negative and in 4% (38/922) of cases, slides reported as monoinfections were, in fact, found to be mixed-species infections. In a minority of cases blood was tested for histidine-rich protein 2 (HRP2) using the Paracheck Pf® (Orchid Biochemical Systems, Goa, India) rapid diagnostic test (RDT).

With the aid of an automated alert system, a research nurse searches the wards for any patient with parasitaemia at least once per day. A research physician then reviews patients to determine the presence of severe disease according to the World Health Organization (WHO) criteria [10],[15]. Respiratory distress (oxygen saturation (off supplemental oxygen) of less than 94% or an age-adjusted elevation in respiratory rate (>32 breaths per minute in adults, >40 breaths per minute in children 5- to 14-years old, >50 breaths per minute in children 2-months to 5-years old, and >60 in babies less than 2-months old), coma (Glasgow Coma Score <11 or Blantyre Coma Score <3) and anaemia (haemoglobin <5 g/dL) are routinely assessed, whereas assessment of the other severity criteria is less systematic as they generally rely on more specialised tests or examinations that are only conducted if clinically indicated.

Death audit

All patients who, according to the prospective surveillance data, had had pure P. vivax infection at any stage during their final admission and who subsequently died at RSMM hospital between January 2004 and September 2009 were eligible for inclusion in the death audit. The data reviewed included 2,937 P. vivax infections and 46 deaths occurring between January 2004 and December 2007 that were included in a previous hospital-based epidemiological analysis [10]. Those diagnosed by RDT alone and those who only received a microscopic diagnosis of vivax malaria before referral to the hospital were excluded from the analysis. Data from the clinical notes were extracted by two physicians experienced in internal medicine. Information was recorded on a standardised death audit form and then entered into an EpiData database (version 3.1, EpiData Association, Odense, Denmark). The audit form documented presenting symptoms, past medical history, examination findings, laboratory and radiological investigation results, fulfilment of ‘severity’ criteria, diagnoses given during admission, treatment received and progress. If Plasmodium species identification was available from both hospital and research cross-check microscopy, the latter was taken as the best available evidence. For the purpose of study exclusion, a positive HRP2-based rapid antigen test (Paracheck Pf®, Orchid Biochemical Systems) was taken as confirmation of P. falciparum infection even if this was not detected on standard microscopy. If available, X-rays were interpreted by a certified infectious diseases specialist who was blinded to case history. Indicators of severity were only deemed to be present if the relevant criteria were fulfilled prior to the preterminal period (defined as within six hours of death).

After all relevant information had been extracted, three certified infectious diseases specialists (coauthors TWY, NMA and RNP) who had not been involved in the data extraction process independently reviewed the clinical data available for each case and subsequently classified the degree to which P. vivax was responsible for the deaths. This was done according to strict a priori criteria based on plausible pathological mechanisms reported in the scientific literature [16] and prior clinical experience with the disease (Table 1). Any disagreements in classification of the cause(s) of death were resolved by consensus. The sole exception to the criteria was for patients who did not fulfil the rules for inclusion in Category 1 (vivax malaria as primary cause of death) but who had no plausible alternative cause of death. In these instances, vivax malaria was classified as the prime cause of death. Although well-established to occur as a result of P. vivax infection alone [16], respiratory distress was only considered to be due to vivax malaria if there was no evidence of concomitant bacterial sepsis, conservatively defined as infiltrates on chest X-ray or any deviation in white cell count from the age-adjusted normal range [17]. Diarrhoea was conservatively attributed to alternative causes. Longitudinal cohorts indicate that P. vivax infection in children results in malnutrition [18], hence severe malnutrition with two or more documented episodes of vivax malaria in the preceding 12 months, was classified as vivax malaria being a major contributor to death.
Table 1

A priori criteria for classifying cause of death

Category

Category description

Clinical criteria

1

Pure vivax malaria the primary cause of death

Potential mechanisms include: coma, extreme anaemia (haemoglobin <3 g/dL), respiratory distress not associated with evidence of sepsisa, acidosis if associated with severe anaemia or splenic rupture

2

Pure vivax malaria likely to have been a major contributor to death

Alternative cause(s) more likely to have led to death but vivax malaria a major contributor through one of the following mechanisms: haemoglobin <7 g/dL, respiratory distress not associated with evidence of bacterial sepsisa, acidosis if associated with haemoglobin <7 g/dL, splenic rupture, decreased consciousness or malnutritionb with two or more documented episodes of vivax malaria in the last year

3

Pure vivax malaria likely to have been a minor contributor to death

Alternative cause(s) more likely to have led to death but vivax malaria a minor contributor through one of the following mechanisms: fever, tachycardia or anaemia (haemoglobin between 7 g/dL and the lower limit of normal)

4

Pure vivax malaria unlikely to have contributed to death

No clear direct pathophysiological mechanism by which vivax malaria could have exacerbated or contributed to the primary cause(s) of death

aSepsis conservatively attributed to bacterial co-infection. Evidence of sepsis defined as consolidation on chest X-ray or any deviation in white cell count from the age-adjusted normal range (birth; 20,000-40,000/mm3, 1 week; 5,000-21,000/mm3, 2 weeks; 5,000-20,000/mm3, 3 months to 12 months; 5,000-15,000/mm3, 1 year to 5 years; 5,000-12,000/mm3, greater than 5 years; 4,000-10,000/mm3).

bMalnutrition defined as documented malnutrition in the notes or a weight-for-age Z-score less than -3, according to the WHO Child Growth Standards [19].

Statistical analyses

Data were analysed in STATA® version 10.1 (StataCorp, College Station, TX, USA) and EpiInfo® version 3.4.3 (Centers for Disease Control and Prevention, Atlanta, GA, USA). Proportions were compared using the chi-square test with Yates’ continuity correction or Fisher’s exact probability test and nonparametric continuous data, such as patient age, were compared using the Mann–Whitney U test. For the purposes of incidence and mortality rate estimation, we assumed a constant study population of 150,000 people (mid-way between the Indonesian government census estimates obtained in 2003 and 2007).

Ethical considerations

This study was approved by the ethics committees of the University of Gadjah Mada, Indonesia (KE.FK.544.EC) and the Menzies School of Health Research, Australia (HREC 2010–1397). Since patients underwent no additional interventions above routine medical care, individual consent was not sought, unless the patient was enrolled in associated studies.

Results

The epidemiology of vivax malaria in Mimika District

Between January 2004 and September 2009 there were an estimated 293,763 clinical or subclinical episodes of vivax malaria in Mimika District [13] resulting in 3,495 admissions to hospital with confirmed P. vivax parasitaemia (Figure 1). The number of patients admitted with malaria showed a bimodal age distribution with peaks between 0 to 10 and 15 to 35 years (Figure 2). The hospital surveillance system identified 845 (24%) patients admitted with P. vivax infection presenting with severe manifestations of malaria: anaemia in 19% (n = 652), respiratory distress in 5.3% (185) and coma in 1.6% (55). The corresponding figures for the 10,821 patients with P. falciparum infection were 23% (2,526) with severe manifestations: severe anaemia in 13% (1,451; P <0.001 for difference compared to P. vivax), respiratory distress in 5.0% (539, P = 0.5) and coma in 2.8% (298, P <0.001). During the same period there were 311 deaths in hospitalised patients with malaria, 65 (21%) of whom were reported to have had pure P. vivax parasitaemia. Based on these data, there were no differences in the age distribution (P = 0.74) or the proportion of females (P = 0.48) or non-Papuans (P = 0.90) in those who died with P. vivax parasitaemia versus those who survived.
Figure 1

Distribution of malaria cases, hospital admissions and deaths in Mimika District between January 2004 and September 2009 (to scale). The figures for the community case work load (overall and febrile) were generated from the hospital surveillance as well as a previous prevalence and treatment seeking survey [13]. Abbreviations: Pf; Plasmodium falciparum, Pv; Plasmodium vivax, Po; Plasmodium ovale, Pm; Plasmodium malariae, Mix; mixed Plasmodium species infection.

Figure 2

Age distribution of patients admitted to Mitra Masyarakat Hospital with malaria between January 2004 and September 2009 by Plasmodium species.

The death audit

In total, 54 (83%) of the 65 relevant clinical charts were available for the death audit (Figure 3). The 11 patients for whom charts were not available had similar baseline characteristics to the remaining 54 patients. Two patients were excluded from the audit because they received their parasitological diagnoses outside of the hospital or their diagnoses were based exclusively on results from a RDT.
Figure 3

Death audit profile.

Blood films were available for cross-checking in 19% (10/52) of the remaining cases (Table 2) and altered the hospital diagnosis from P. vivax monoinfection to mixed P. vivax/P. falciparum infection in one case. Paracheck Pf® (Orchid Biochemical Systems) tests were performed in 19% (10/52) of cases and altered the diagnosis for one further case from P. vivax to mixed infection. On review of the notes and the above laboratory findings, a total of 12 of 52 cases (23%) had been incorrectly coded as infection with pure P. vivax infections. Six of these cases had been reclassified as mixed infections and six were due to coding errors. The remaining 40 (77%) patients had pure P. vivax parasitaemia according to the best available evidence. Chest X-rays were available for review in 26 of these cases.
Table 2

Clinical details of the patients whose deaths were associated with vivax malaria

Category

No.

Age

Time to death

Weight (kg)

Documented malnutrition

Documented Pv in last year

Vivax parasitaemia

Haemoglobin (g/dL)

White cell count (μl -1)

Platelets × 10 3 μl -1

Bilirubin (mmol/L)

Creatinine (μmol/L)

Glucose (mmol/L)

Bicarbonate (mmol/L)

CXR

Individual assessors’ classifications

Primary cause of death

Indirect causes

1. Primary cause

1

19y

1d

40

N

2

++++

2.2

7,000

11

135.6

105

8.2

-

-

1,1,1

Vivax malaria with extreme anaemia associated with hyperbilirubinaemia

 

2a

1y7m

1d

7

Y

1

++

4.7

8,000

142

-

-

-

-

-

1,1,1

Vivax malaria

Malnutrition

3

24y

4d

56

N

0

++++

2.6

16100

51

29.2

248

6.1

-

Resolving minor RLL consolidation compared with film 1 month prior

1,1,1

Vivax malaria with extreme anaemia and renal failure

 

4b

10 m

3d

7

Y

0

++++

1.9

11,800

64

-

-

13.5

3.0

Day 0 – normal Day 2 – whiteout of R lung and part of L lung. Pulmonary oedema in remainder of L lung

1,1,1

Vivax malaria with extreme anaemia and respiratory distress associated with acidosis

Malnutrition

5

1y9m

2d

11

N

0

++++

1.7

20,100

139

116.3

-

5.6

-

-

1,1,1

Vivax malaria with extreme anaemia associated with hyperbilirubinaemia

Possible underlying sepsis

2. Major contributor

6

3m26d

5 h

-

N

0

+

2.8

29,000

123

-

-

6.5

-

Normal

1,1,2

Vivax malaria with extreme anaemia

Possible underlying sepsis

7a

4y4m

2d

10

Y

0

++++

8.6

14,300

13

13.5

-

4.8

-

Normal

2,2,2

Respiratory tract infection

Malnutrition Vivax malaria

8a

3y1m

3 h

12

N

0

++

-

-

-

-

-

-

-

Normal

2,2,2

Respiratory tract infection

Vivax malaria

9

1y9m

7d

8

Y

3

+++

9.2

11,000

163

-

-

-

-

-

1,2,2

Malnutrition with sepsis

Vivax malaria

10

1y8m

4d

8

Y

0

++++

5.1

4,200

154

-

-

-

-

Poor inspiratory effort, unable to assess

2,2,2

Respiratory tract infection

Malnutrition Vivax malaria

11

1y8m

1d

-

Y

0

+++

7.3

13,900

13

-

56

21.8

 

Normal

1,2,3

Respiratory tract infection

Vivax malaria Malnutrition

12a

1y3m

9d

6

Y

3

+++

12.5

25,300

136

5.3

-

6.8

 

-

2,2,3

Diarrhoeal disease

Malnutrition Vivax malaria

13

1y

7d

6

Y

0

++

7.9

8,300

105

-

43

4.6

9.8

Normal

3,2,2

Diarrhoeal disease associated with acidosis

Vivax malaria Malnutrition

14

38y

13d

26

Y

0

+++

6.3

14,300

55

-

106

6.0

-

Minor chronic changes in LLL

2,2,2

AIDS

Vivax malaria Malnutrition

15

2y

2d

12

Y

0

+

4.4

10,600

21

23.4

48

4.3

26.7

Evidence of pneumonia

2,2,2

Respiratory tract infection

Vivax malaria Malnutrition

16

1y5m

17d

5

Y

3

++

6.7

9,500

262

-

-

6.0

-

Diffuse changes consistent with pneumonia, R > L

2,2,2

AIDS

Vivax malaria Malnutrition Tuberculosis

17

27y

5d

-

N

1

+

6.5

3,800

80

-

-

-

19.2

-

2,2,2

AIDS

Vivax malaria

18

1y23d

6 h

9

N

0

+++

5.8

4,700

229

-

44

8.7

9.3

RUL consolidation

2,2,2

Bronchopneumonia associated with acidosis

Vivax malaria

19

34y

8 h

50

N

0

++

5.8

14,100

252

-

-

4.9

2.2

Bilaterally increased lung markings, R > L, consistent with ARDS or pneumonia

2,2,2

Chronic renal failure associated with acidosis

Vivax malaria Respiratory tract infection

20b

61y

6d

50

N

0

+

4.1

3,500

9

21.7

2378

5.3

13.6

RML collapse with consolidation, calcification and scarring

2,2,2

Chronic renal failure with respiratory tract infection associated with acidosis

Vivax malaria

21a,b

25y

5 h

75

N

0

+

6.2

23,700

22

-

97

15.4

-

-

2,2,2

GI bleeding secondary to NSAID

Vivax malaria

22b

3y

1d

11

N

0

++

9.4

9,600

152

-

114

1.7

13.3

Admission – underexposed but probably normal Later in the day – collapsed L lung with ETT in R main bronchus. R lung normal

2,2,2

Sepsis associated with hypoglycaemia and acidosis

Vivax malaria Trauma

23b

14y

8d

-

N

0

+++

2.1

4,200

89

19.0

1680

-

2.2

-

2,2,3

Uraemia secondary to endstage chronic renal failure associated with acidosis

Vivax malaria exacerbating severe anaemia

3. Minor contributor

24

2y4m

6d

9

Y

1

++

13.0

12,600

231

40.4

-

6.9

-

-

2,3,3

Diarrhoeal disease

Sepsis Malnutrition Vivax malaria

25

59y

3d

50

N

0

+

10.5

35,500

173

33.5

228

4.2

-

-

3,3,3

Respiratory sepsis

COPD Vivax malaria Ischemic heart disease

26

2y10m

5d

12

Y

1

+

9.0

13200

124

-

12

5.8

22.8

Dense, bilateral patchy consolidation L > R

3,3,3

Tuberculosis with sepsis

Vivax malaria Malnutrition

27a

18y

1d

50

N

0

++

15.5

16,100

100

-

332

11.4

17.1

Normal

3,3,3

Meningitis associated with renal failure

Vivax malaria

28a

60y

1d

37

N

0

+

11.5

11,800

119

-

600

5.7

-

-

3,3,4

Hepatorenal syndrome

Vivax malaria Possible bacterial infection

29

1y8m

1d

7

N

1

++

9.8

79,300

580

-

-

2.4

9.9

CXR 2 days prior showed infiltrate obscuring L heart border

3,3,3

Respiratory tract infection with overwhelming sepsis and acidosis

Vivax malaria Malnutrition

30

24y

5d

33

N

2

+

4.7

1,500

85

6.7

132

5.7

21.9

Worsening RML consolidation and cavitation compared with previous films. L mid and lower zone consolidation and cavitation. R mediastinal mass

3,3,3

AIDS with tuberculosis

Vivax malaria

31

5m4d

12d

7

N

0

++

13.0

7,200

107

-

-

-

13.9

Infiltrate at R hilum

3,4,3

Bronchopneumonia associated with acidosis

Vivax malaria

32

1y8m

1d

6

Y

0

++++

10.2

19,700

110

-

66

1.2

-

Normal

3,3,3

Diarrhoeal disease with hypovolaemic shock

Vivax malaria Malnutrition

33

55y

4d

60

N

0

++++

10.1

19,500

55

-

521

3.7

-

Increased lung markings bilaterally

3,3,3

Sepsis and renal failure

Vivax malaria

34

4y

1d

16

N

0

+

11.2

22,700

461

-

-

6.0

-

-

3,3,3

GI sepsis

Vivax malaria

35

31y

10d

38

Y

1

+

9.9

3,700

114

3.4

131

4.6

-

-

3,3,3

HIV associated enteropathy

Malnutrition Vivax malaria

36

3y6m

15d

12

Y

2

++

8.9

27,700

3

63.3

-

-

33.2

Poor inspiratory effort, unable to assess

3,3,4

Respiratory tract infection with overwhelming sepsis associated with hyperbilirubinaemia

Malnutrition Vivax malaria

aResearch microscopy done; bParacheck Pf® done. AIDS; acquired immunodeficiency syndrome, ARDS; acute respiratory distress syndrome, CXR; chest X-ray, d; day, h; hour, ETT; endotracheal tube, GI; gastrointestinal, HIV; human immunodeficiency virus, L; left, LLL; left lower lobe, m; month, NSAID; non-steroidal anti-inflammatory drug, Pv; Plasmodium vivax, R; right, RLL; right lower lobe, RML; right middle lobe, RUL; right upper lobe, y; year. To comply with the BMC policy on patient confidentiality, details on gender were removed from the table to ensure there were less than three indirect identifiers per patient.

Four patients died of causes thought unlikely to be related to P. vivax infection (Figure 3); two due to road traffic accidents, one due to electrocution and one due to tuberculous meningoencephalitis. These patients were excluded from further analysis. The remaining patients were classified as Category 1 (P. vivax infection the prime cause of death) in 6 cases, Category 2 (P. vivax infection a major contributor) in 17 cases and Category 3 (P. vivax infection a minor contributor) in 13 cases. Of these 36 patients, 23 (64%) had presented to the hospital in the 12 months preceding their death. The median number of preceding presentations was 5 (range 1 to 17) and the proportion of these presentations due to malaria was 25% (41/161). Malnutrition was recorded in 16 (44%) patients and was present in 64% (14/22) of children less than five-years old who died compared to 14% (2/14) of those five-years old and older. Patients who had presented to the hospital with malaria over the preceding 12 months were at greater risk of malnutrition (59%, 10/17) compared to those with no documentation of prior presentation with malaria (31%, 6/19), although this did not reach statistical significance (P = 0.18).

The median age of the patients in Category 1 was 1.7 years (interquartile (IQ) range 0.71 to 21 years), 3.0 years (IQ range 1.5 to 26 years) in Category 2 and 4 years (IQ range 2.0 to 43 years) in Category 3, P = 0.23. There was a predominance of females in all three categories (83% (5/6), 77% (13/17) and 54% (7/13), respectively), although this was also the case in hospitalised patients with vivax malaria as a whole (60% (2,081/3,495)).

Overall, the most prominent manifestation of severity was respiratory distress which was present in 74% (26) of the 35 patients in whom this could be assessed. In total, 83% (19/23) of children (≤15 years) had respiratory distress compared with 58% (7/12) of adults; P = 0.36. Respiratory distress was present in all of the ten patients with severe anaemia compared to only 62% (15/24) of those patients without severe anaemia; P = 0.07.

Four (13%) of the 31 patients in whom a Glasgow or Blantyre Coma Score was reported fulfilled criteria for cerebral malaria prior to the preterminal period (Table 2 patients #14, #22, #27 and #32). In one case a lumbar puncture was suggestive of bacterial meningitis. The other three deaths were not deemed to be primarily attributable to vivax malaria.

Haematology testing was available in 97% (35/36) of patients in the death audit. There was a non-statistically significant association between anaemia and acidosis (rs = 0.45, P = 0.09; Figure 4). Severe anaemia was present in 29% (10/35) and acidosis in 64% (9/15) of patients who had blood gas analyses (three of the acidotic patients also had severe anaemia and eight had respiratory distress). Severe thrombocytopaenia was relatively common with 19% (7/35) of patients having a platelet concentration of less than 50 × 109 per litre and 14% (5/35) less than 20 × 109 per litre. Three of the 13 patients tested (23%) fulfilled the WHO criterion for hyperbilirubinaemia (>42.75 mmol/L), two of whom succumbed to vivax malaria as a direct cause of death. Two of the 28 patients assessed (7%) had hypoglycaemia (glucose <2.2 mmol/L). Six of nineteen patients assessed (32%) had a creatinine concentration above 230 μmol/L (the WHO criterion for severe malaria).
Figure 4

Relationship between anaemia and acidosis in vivax-associated deaths. Diamond = Category 1, Squares = Category 2 and Triangles = Category 3. rs = 0.45, P = 0.09.

Three recurring patterns, and potential mechanisms, of death emerged. The first mechanism was extreme anaemia (haemoglobin <3 g/dL) which was deemed to be the cause of death in five of the six (83%) patients in Category 1. The second was a combination of severe malnutrition and vivax malaria, often with additional sepsis with respiratory or gastrointestinal manifestations. Overall, 16 (44%) of the 36 vivax-associated deaths were in patients with documented malnutrition, including three patients who had a WHO weight-for-age Z-score of less than −3 [19]. The third pattern constituted vivax malaria in association with chronic or subacute morbidity, such as chronic kidney disease (n =3), HIV infection (n =5) or active tuberculosis (n =2).

Overall risks

After correcting for errors in parasite species identification, P. vivax was found to have caused or contributed to a minimum of 36 deaths over the 69-month accrual period, corresponding to a minimum case fatality of 10.3 per 1,000 (36/3,495) hospitalised patients with P. vivax infection (Table 3). From the concurrent community surveillance and a household survey of treatment seeking behaviour [13] an estimated 293,763 cases of vivax parasitaemia occurred in Mimika District over the study accrual period, giving rise to an overall estimated minimum case fatality rate of 0.12 per 1,000 infections. The upper limits for the hospital and community fatality estimates were 16.9 and 0.63 per 1,000, respectively (see the footnote of Table 3 for the assumptions underlying this sensitivity analysis). The case fatality of vivax malaria in children under five years of age compared with those five years of age or older was 14.9 versus 7.0 per 1,000 in the hospital and 0.26 versus 0.07 per 1,000 in the community.
Table 3

Case fatality per 1,000 patients with vivax malaria

 

Hospitalised patients

Overall population b

Age group

Minimum (n/D)

Upper limit a(n/D)

Minimum (n/D)

Upper limit (n/D)

<5 years

14.9

19.6

0.26

1.13

(95% CI 9.3 to 22.4)

(95% CI 13.1 to 28.0)

(95% CI 0.16 to 0.40)

(95% CI 0.87 to 1.33)

(22/1,480c)

(29/1,480)

(22/84,028)

(90.6/84,028)

≥5 years

7.0

15.1

0.07

0.45

(95% CI 3.9 to 11.8)

(95% CI 10.2 to 21.5)

(95% CI 0.04 to 0.11)

(95% CI 0.36 to 0.55)

(14/1,986c)

(30/1,986)

(14/209,735)

(93.8/209,735)

All

10.3

16.9

0.12

0.63

(95% CI 7.2 to 14.20

(95% CI 12.9 to 21.7)

(95% CI 0.09 to 0.17)

(95% CI 0.54 to 0.72)

(36/3,495)

(59/3,495)

(36/293,763)

(184.4/293,763)

aUpper limits were calculated assuming the following: 1) all of the patients for whom notes were not available died of causes related to P. vivax infection; 2) an equal number of deaths were miscoded as being attributable to P. falciparum as were miscoded as being attributable to P. vivax; bdenominators include hospital and community patients with P. vivax, estimated from the total number of cases seen in our community surveillance network multiplied by the reciprocal of the proportion who sought treatment at our network facilities (40%, established from a house-to-house survey of treatment seeking behaviour [3]). To calculate the upper limits, the same assumptions were made as in the hospitalised patients except we also multiplied the number of deaths by the reciprocal of 32% (the proportion of deaths estimated to occur outside of hospital (unpublished data)); ca small proportion of individuals in the active surveillance had an unknown age. N; number, D; denominator.

Discussion

Over recent years, malariometric surveillance in southern Papua has identified a significant number of individuals who have died following P. vivax infection. Our previous publication based on an earlier set of surveillance data reported an overall risk of death in patients admitted with vivax malaria of 1.6%, raising significant concerns that the virulence of this organism had been underestimated [10]. In the current analysis we used a priori definitions to classify the contribution of vivax malaria to those deaths. We excluded individuals with mixed Plasmodium species infections and used conservative criteria to define potential concomitant bacterial sepsis. Our results highlight that over a six year period, a minimum of 36 deaths could be at least partially attributed to P. vivax infection and that in six cases vivax malaria was most likely the primary cause of death. This resulted in a fatality of 1 in 97 for patients admitted to hospital and 1 in 8,160 for the community as a whole. Children younger than five years old were at a two- to four-fold greater risk of death compared to those older than five years.

Five of the patients in the study died of extreme anaemia (probably as a result of high-output cardiac failure and acidosis), while severe anaemia was a major contributor in five other fatal cases. A study from Venezuela suggests that in areas of mixed species endemicity, anaemia may be a more frequent and severe sequel of vivax compared with falciparum malaria [20]. In Timika, the mean reduction in haemoglobin and risk of severe anaemia is greater for infants (<1 year of age) infected with P. vivax when compared with P. falciparum and, thereafter, the haematologic impact of P. falciparum exceeds that of P. vivax, [3],[21]. We have shown previously that 12% of all deaths at the RSMM are attributable to patients with severe anaemia and overall 6% of all cases of severe anaemia are attributed to vivax malaria [3].

Overall, nearly half (44%) of the vivax-associated deaths had evidence of malnutrition and a high proportion of these individuals also had clinical or radiological evidence of possible concomitant bacterial infection. Chronic P. vivax infections have been implicated in a protein-wasting condition akin to kwashiorkor, in both induced [22] and natural infection [23]. Indeed, the evidence that P. vivax causes malnutrition is stronger than that for P. falciparum [24]. It is also likely that there is an epidemiological, and possibly a biological, association between malnutrition and a greater risk of P. vivax severe disease [25], as has been noted previously in patients infected with P. falciparum [26]. While this relationship is likely bidirectional, our study supports previous literature suggesting that malnutrition significantly worsens the outcome of infectious disease and implicates vivax malaria as not only a potential cause of malnutrition, but also a subsequent precipitating cause of death in those with significant malnutrition [16].

More than 70% of audited individuals fulfilled the criteria for respiratory distress. Previous work has suggested that vivax-associated lung dysfunction may occur from an inflammatory response in the pulmonary microvasculature, exacerbated by treatment [27], causing increased capillary permeability, alveolar endothelial damage and chest X-ray infiltrates [28]-[30]. One infant had an acute respiratory distress-type picture. Bilateral lung infiltrates consistent with acute lung injury were seen in 15% of all adult vivax-associated deaths and in a third of those who had chest X-rays. Severe anaemia and metabolic acidosis are also likely to be key determinants, particularly in children, in whom lung injury is less common than in adults. Eight of the nine patients with acidosis were found to be in respiratory distress as were all ten patients with severe anaemia.

Studies of P. falciparum infection in African children have shown high coprevalence of pneumonia, meningitis and bacteraemia in children with severe malaria [31]-[33], the largest of which demonstrated a strong association between coinfection and an increased risk of death [33]. A study in Papua New Guinea has also highlighted the importance of respiratory distress in vivax malaria, although the degree to which this was attributable to P. vivax infection, associated anaemia or comorbid pneumonia was unclear [34]. Since microbiological data were not available in our study, we conservatively regarded any deviation in white cell count or infiltrates on chest X-ray as evidence of concomitant bacterial infection. In other studies, albeit without routine blood cultures for bacteraemia, severe and fatal sepsis syndromes have been attributed to vivax malaria [35]. Given the potential for P. vivax to cause an intense inflammatory response [36] and/or lung injury/infiltrates [27] it is likely that we have significantly overestimated the contribution of infectious comorbidities and underestimated the direct contribution of vivax malaria alone to sepsis, lung injury and death. Nevertheless, our results suggest that, as with falciparum malaria, there may be a potentially fatal interaction between vivax malaria and bacterial infection, particularly pneumonia. To clarify this interaction, prospective studies of severe vivax malaria syndromes need to include systematic investigation for concomitant bacterial infection, including blood cultures [37]. Until then, our findings suggest the need for aggressive antimalarial treatment in patients with evidence of coinfection, and also indicate that mono-infected patients with vivax malaria who show signs of severe disease should be investigated and treated for associated bacterial sepsis.

HIV infection is now recognised as a major contributor to the development of severe and fatal disease in P. falciparum malaria [38]. Fourteen percent of vivax-associated deaths were in patients with documented HIV co-infection, which, with the recent rapid increase in HIV infection in Papua [39] and the retrospective study design, is likely to be an underestimate of its contribution. While P. vivax may act as the final precipitating cause of death in HIV infected individuals, a potential role for HIV in exacerbating the severity of vivax malaria, as occurs with P. falciparum, requires further investigation.

Our study has several important limitations. According to laboratory reports, 12 of the 54 patients in the death audit were actually shown to be suffering from P. falciparum or mixed species infections. Since we did not systematically review all P. falciparum deaths, it is possible that similar miscoding occurred in the opposite direction (for example low density P. vivax parasitaemia missed on blood smear examination). This would have resulted in an underestimation of the true incidence of deaths due to P. vivax infection. Our sensitivity analysis reported in Table 3 assumes that an equal number of deaths were miscoded as being attributable to P. falciparum as were miscoded as being attributable to P. vivax.

Differentiating P. vivax from P. falciparum early ring (trophozoite) stages using standard microscopy is fraught with error. Despite high concordance (90%) of hospital microscopy results and an independent expert’s findings, it is likely that a degree of misdiagnosis occurred, even in cases where cross-check microscopy was performed. Fully quantifiable parasitaemias were not available to the adjudicating physicians; however, the semi-quantitative scoring gave an indication of relative parasite density.

Rapid diagnostic tests were only done in a minority of cases. Most HRP2-based tests have been shown to be highly sensitive for the detection of falciparum malaria; therefore, a significant biomass of P. falciparum would have been unlikely in patients who tested negative [40]. For the remaining patients, it is possible that microscopy may have missed subpatent P. falciparum parasitaemias. Siripoon et al. found that 13% of patients who had been diagnosed with P. vivax monoinfections in Thailand also had subpatent P. falciparum infections based on PCR testing [41]. Because PCR diagnostics are still not widely available in endemic areas, this is unlikely to have a bearing on the clinical classification of malaria or its treatment. It does, however, limit our ability to categorically incriminate P. vivax monoinfection as a cause of fatal disease.

Previous treatment seeking studies in southern Papua estimate that almost 68% of deaths occur outside of hospital (unpublished data). We incorporated this crude proportion in the sensitivity analysis but were unable to make more subtle adjustments based on differences in the demographic and causative distribution of those deaths.

Conclusion

We have shown that in southern Papua, mortality primarily attributable to P. vivax infection may occur but that indirect contribution to death in those with comorbidities, such as malnutrition, HIV and possible bacterial sepsis, is a more common scenario. Future research should include postmortem studies and detailed clinical and microbiological investigations of severe cases of vivax malaria to characterise pathogenic mechanisms and elucidate better therapeutic strategies by which fatal outcomes may be averted [42]. If the overall burden of P. vivax is to be appreciably decreased, practical, short-course, sterilising drug regimens must be developed that reliably prevent relapses and reduce transmission of this complicated disease.

Financial support

The Timika Research Facility and Papuan Community Health Foundation were supported by AusAID (Australian Agency for International Development, Department of Foreign Affairs and Trade). NMD was funded by the Rhodes Trust. The study was funded by the Wellcome Trust (Senior Fellowship in Clinical Science to RNP 091625) and the National Health and Medical Research Council of Australia (Program Grants 496600 and 1037304; Fellowships to NMA, APR, TWY). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Declarations

Acknowledgements

We are grateful to Lembaga Pengembangan Masyarakat Amungme Kamoro (LPMAK), the staff of Rumah Sakit Mitra Masyarakat, PT Freeport Indonesia Public Health & Malaria Control Department and International SOS for their support and technical assistance.

Authors’ Affiliations

(1)
Global Health Division, Menzies School of Health Research and Charles Darwin University
(2)
Centre for Tropical Medicine, Nuffield Department of Medicine, University of Oxford
(3)
Papuan Health and Community Development Foundation
(4)
District Health Authority
(5)
Department of Paediatrics, Faculty of Medicine, Gadjah Mada University
(6)
Division of Medicine, Royal Darwin Hospital
(7)
Public Health & Malaria Control Department, International SOS, PT Freeport Indonesia
(8)
Department of Entomology, Faculty of Agriculture, Kasetsart University
(9)
Mitra Masyarakat Hospital

References

  1. Guerra CA, Howes RE, Patil AP, Gething PW, Van Boeckel TP, Temperley WH, Kabaria CW, Tatem AJ, Manh BH, Elyazar IR, Baird JK, Snow RW, Hay SI: The international limits and population at risk of Plasmodium vivax transmission in 2009. PLoS Negl Trop Dis. 2010, 4: e774-10.1371/journal.pntd.0000774.View ArticlePubMedPubMed CentralGoogle Scholar
  2. Gething PW, Elyazar IR, Moyes CL, Smith DL, Battle KE, Guerra CA, Patil AP, Tatem AJ, Howes RE, Myers MF, George DB, Horby P, Wertheim HF, Price RN, Müeller I, Baird JK, Hay SI: A long neglected world malaria map: Plasmodium vivax endemicity in 2010. PLoS Negl Trop Dis. 2012, 6: e1814-10.1371/journal.pntd.0001814.View ArticlePubMedPubMed CentralGoogle Scholar
  3. Douglas NM, Lampah DA, Kenangalem E, Simpson JA, Poespoprodjo JR, Sugiarto P, Anstey NM, Price RN: Major burden of severe anemia from non-falciparum malaria species in Southern Papua: a hospital-based surveillance study. PLoS Med. 2013, 10: e1001575-10.1371/journal.pmed.1001575.View ArticlePubMedPubMed CentralGoogle Scholar
  4. Poespoprodjo JR, Fobia W, Kenangalem E, Lampah DA, Warikar N, Seal A, McGready R, Sugiarto P, Tjitra E, Anstey NM, Price RN: Adverse pregnancy outcomes in an area where multidrug-resistant plasmodium vivax and Plasmodium falciparum infections are endemic. Clin Infect Dis. 2008, 46: 1374-1381. 10.1086/586743.View ArticlePubMedPubMed CentralGoogle Scholar
  5. McGready R, Lee SJ, Wiladphaingern J, Ashley EA, Rijken MJ, Boel M, Simpson JA, Paw MK, Pimanpanarak M, Mu O, Singhasivanon P, White NJ, Nosten FH: Adverse effects of falciparum and vivax malaria and the safety of antimalarial treatment in early pregnancy: a population-based study. Lancet Infect Dis. 2012, 12: 388-396. 10.1016/S1473-3099(11)70339-5.View ArticlePubMedPubMed CentralGoogle Scholar
  6. Baird JK: Evidence and implications of mortality associated with acute Plasmodium vivax malaria. Clin Microbiol Rev. 2013, 26: 36-57. 10.1128/CMR.00074-12.View ArticlePubMedPubMed CentralGoogle Scholar
  7. Price RN, Douglas NM, Anstey NM: New developments in Plasmodium vivax malaria: severe disease and the rise of chloroquine resistance. Curr Opin Infect Dis. 2009, 22: 430-435. 10.1097/QCO.0b013e32832f14c1.View ArticlePubMedGoogle Scholar
  8. Barcus MJ, Basri H, Picarima H, Manyakori C: Sekartuti, Elyazar I, Bangs MJ, Maguire JD, Baird JK: Demographic risk factors for severe and fatal vivax and falciparum malaria among hospital admissions in northeastern Indonesian Papua . Am J Trop Med Hyg. 2007, 77: 984-991.PubMedGoogle Scholar
  9. Rodriguez-Morales AJ, Benitez JA, Arria M: Malaria mortality in Venezuela: focus on deaths due to plasmodium vivax in children. J Trop Pediatr. 2008, 54: 94-101. 10.1093/tropej/fmm074.View ArticlePubMedGoogle Scholar
  10. Tjitra E, Anstey NM, Sugiarto P, Warikar N, Kenangalem E, Karyana M, Lampah DA, Price RN: Multidrug-resistant plasmodium vivax associated with severe and fatal malaria: a prospective study in Papua. Indonesia. PLoS Med. 2008, 5: e128-10.1371/journal.pmed.0050128.View ArticlePubMedGoogle Scholar
  11. Lacerda MV, Fragoso SC, Alecrim MG, Alexandre MA, Magalhaes BM, Siqueira AM, Ferreira LC, Araujo JR, Mourao MP, Ferrer M, Castillo P, Martin-Jaular L, Fernandez-Becerra C, del Portillo H, Ordi J, Alonso PL, Bassat Q: Postmortem characterization of patients with clinical diagnosis of Plasmodium vivax malaria: to what extent does this parasite kill?. Clin Infect Dis. 2012, 55: e67-e74. 10.1093/cid/cis615.View ArticlePubMedGoogle Scholar
  12. Ratcliff A, Siswantoro H, Kenangalem E, Maristela R, Wuwung RM, Laihad F, Ebsworth EP, Anstey NM, Tjitra E, Price RN: Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison. Lancet. 2007, 369: 757-765. 10.1016/S0140-6736(07)60160-3.View ArticlePubMedPubMed CentralGoogle Scholar
  13. Karyana M, Burdarm L, Yeung S, Kenangalem E, Wariker N, Maristela R, Umana KG, Vemuri R, Okoseray MJ, Penttinen PM, Ebsworth P, Sugiarto P, Anstey NM, Tjitra E, Price RN: Malaria morbidity in Papua Indonesia, an area with multidrug resistant Plasmodium vivax and Plasmodium falciparum. Malar J. 2008, 7: 148-10.1186/1475-2875-7-148.View ArticlePubMedPubMed CentralGoogle Scholar
  14. Randall LM, Kenangalem E, Lampah DA, Tjitra E, Mwaikambo ED, Handojo T, Piera KA, Zhao ZZ, de Labastida Rivera F, Zhou Y, McSweeney KM, Le L, Amante FH, Haque A, Stanley AC, Woodberry T, Salwati E, Granger DL, Hobbs MR, Price RN, Weinberg JB, Montgomery GW, Anstey NM, Engwerda CR: Age-related susceptibility to severe malaria associated with galectin-2 in highland Papuans. J Infect Dis. 2010, 202: 117-124. 10.1086/653125.View ArticlePubMedPubMed CentralGoogle Scholar
  15. Severe falciparum malaria. World Health Organization, Communicable Diseases Cluster. Trans R Soc Trop Med Hyg 2000, 94:S1–S90.Google Scholar
  16. Anstey NM, Douglas NM, Poespoprodjo JR, Price RN: Plasmodium vivax: clinical spectrum, risk factors and pathogenesis. Adv Parasitol. 2012, 80: 151-201. 10.1016/B978-0-12-397900-1.00003-7.View ArticlePubMedGoogle Scholar
  17. Dipchand AI: The HSC Handbook of Pediatrics. 1997, Mosby, St Louis, 9Google Scholar
  18. Lee G, Yori P, Olortegui MP, Pan W, Caulfield L, Gilman RH, Sanders JW, Delgado HS, Kosek M: Comparative effects of vivax malaria, fever and diarrhoea on child growth. Int J Epidemiol. 2012, 41: 531-539. 10.1093/ije/dyr190.View ArticlePubMedPubMed CentralGoogle Scholar
  19. The WHO Child Growth Standards. [], [http://www.who.int/childgrowth/en/]
  20. Rodriguez-Morales AJ, Sanchez E, Vargas M, Piccolo C, Colina R, Arria M, Franco-Paredes C: Is anemia in Plasmodium vivax malaria more frequent and severe than in Plasmodium falciparum?. Am J Med. 2006, 119: e9-e10. 10.1016/j.amjmed.2005.08.014.View ArticlePubMedGoogle Scholar
  21. Poespoprodjo JR, Fobia W, Kenangalem E, Lampah DA, Hasanuddin A, Warikar N, Sugiarto P, Tjitra E, Anstey NM, Price RN: Vivax malaria: a major cause of morbidity in early infancy. Clin Infect Dis. 2009, 48: 1704-1712. 10.1086/599041.View ArticlePubMedPubMed CentralGoogle Scholar
  22. Kitchen SF: Malariology. 1939, W. B. Saunders & Co., LondonGoogle Scholar
  23. Hutchinson RA, Lindsay SW: Malaria and deaths in the English marshes. Lancet. 2006, 367: 1947-1951. 10.1016/S0140-6736(06)68850-8.View ArticlePubMedGoogle Scholar
  24. Williams TN, Maitland K, Phelps L, Bennett S, Peto TE, Viji J, Timothy R, Clegg JB, Weatherall DJ, Bowden DK: Plasmodium vivax: a cause of malnutrition in young children. QJM. 1997, 90: 751-757. 10.1093/qjmed/90.12.751.View ArticlePubMedGoogle Scholar
  25. Lanca EF, Magalhaes BM, Vitor-Silva S, Siqueira AM, Benzecry SG, Alexandre MA, O’Brien C, Bassat Q, Lacerda MV: Risk factors and characterization of Plasmodium vivax-associated admissions to pediatric intensive care units in the Brazilian Amazon. PLoS One. 2012, 7: e35406-10.1371/journal.pone.0035406.View ArticlePubMedPubMed CentralGoogle Scholar
  26. Berkley JA, Bejon P, Mwangi T, Gwer S, Maitland K, Williams TN, Mohammed S, Osier F, Kinyanjui S, Fegan G, Lowe BS, English M, Peshu N, Marsh K, Newton CR: HIV infection, malnutrition, and invasive bacterial infection among children with severe malaria. Clin Infect Dis. 2009, 49: 336-343. 10.1086/600299.View ArticlePubMedPubMed CentralGoogle Scholar
  27. Anstey NM, Handojo T, Pain MC, Kenangalem E, Tjitra E, Price RN, Maguire GP: Lung injury in vivax malaria: pathophysiological evidence for pulmonary vascular sequestration and posttreatment alveolar-capillary inflammation. J Infect Dis. 2007, 195: 589-596. 10.1086/510756.View ArticlePubMedPubMed CentralGoogle Scholar
  28. Tan LK, Yacoub S, Scott S, Bhagani S, Jacobs M: Acute lung injury and other serious complications of Plasmodium vivax malaria. Lancet Infect Dis. 2008, 8: 449-454. 10.1016/S1473-3099(08)70153-1.View ArticlePubMedGoogle Scholar
  29. Price L, Planche T, Rayner C, Krishna S: Acute respiratory distress syndrome in Plasmodium vivax malaria: case report and review of the literature. Trans R Soc Trop Med Hyg. 2007, 101: 655-659. 10.1016/j.trstmh.2007.02.014.View ArticlePubMedGoogle Scholar
  30. Taylor WR, Hanson J, Turner GD, White NJ, Dondorp AM: Respiratory manifestations of malaria. Chest. 2012, 142: 492-505. 10.1378/chest.11-2655.View ArticlePubMedGoogle Scholar
  31. Bronzan RN, Taylor TE, Mwenechanya J, Tembo M, Kayira K, Bwanaisa L, Njobvu A, Kondowe W, Chalira C, Walsh AL, Phiri A, Wilson LK, Molyneux ME, Graham SM: Bacteremia in Malawian children with severe malaria: prevalence, etiology, HIV coinfection, and outcome. J Infect Dis. 2007, 195: 895-904. 10.1086/511437.View ArticlePubMedGoogle Scholar
  32. Berkley JA, Mwangi I, Mellington F, Mwarumba S, Marsh K: Cerebral malaria versus bacterial meningitis in children with impaired consciousness. QJM. 1999, 92: 151-157. 10.1093/qjmed/92.3.151.View ArticlePubMedGoogle Scholar
  33. Gwer S, Newton CR, Berkley JA: Over-diagnosis and co-morbidity of severe malaria in African children: a guide for clinicians. Am J Trop Med Hyg. 2007, 77: 6-13.PubMedPubMed CentralGoogle Scholar
  34. Genton B, D’Acremont V, Rare L, Baea K, Reeder JC, Alpers MP, Muller I: Plasmodium vivax and mixed infections are associated with severe malaria in children: a prospective cohort study from Papua New Guinea. PLoS Med. 2008, 5: e127-10.1371/journal.pmed.0050127.View ArticlePubMedPubMed CentralGoogle Scholar
  35. Andrade BB, Reis-Filho A, Souza-Neto SM, Clarencio J, Camargo LM, Barral A, Barral-Netto M: Severe Plasmodium vivax malaria exhibits marked inflammatory imbalance. Malar J. 2010, 9: 13-10.1186/1475-2875-9-13.View ArticlePubMedPubMed CentralGoogle Scholar
  36. Yeo TW, Lampah DA, Tjitra E, Piera K, Gitawati R, Kenangalem E, Price RN, Anstey NM: Greater endothelial activation, Weibel-Palade body release and host inflammatory response to Plasmodium vivax, compared with Plasmodium falciparum: a prospective study in Papua, Indonesia. J Infect Dis. 2010, 202: 109-112. 10.1086/653211.View ArticlePubMedPubMed CentralGoogle Scholar
  37. Bhattacharya SK, Sur D, Dutta S, Kanungo S, Ochiai RL, Kim DR, Anstey NM, von Seidlein L, Deen J: Vivax malaria and bacteraemia: a prospective study in Kolkata. India Malar J. 2013, 12: 176-10.1186/1475-2875-12-176.View ArticlePubMedGoogle Scholar
  38. Bejon P, Berkley JA, Mwangi T, Ogada E, Mwangi I, Maitland K, Williams T, Scott JA, English M, Lowe BS, Peshu N, Newton CR, Marsh K: Defining childhood severe falciparum malaria for intervention studies. PLoS Med. 2007, 4: e251-10.1371/journal.pmed.0040251.View ArticlePubMedPubMed CentralGoogle Scholar
  39. Pontororing GJ, Kenangalem E, Lolong DB, Waramori G, Sandjaja , Tjitra E, Price RN, Kelly PM, Anstey NM, Ralph AP, Sandjaja SS, Tjitra E, Price RN, Kelly PM, Anstey NM, Ralph AP: The burden and treatment of HIV in tuberculosis patients in Papua Province, Indonesia: a prospective observational study. BMC Infect Dis. 2010, 10: 362-10.1186/1471-2334-10-362.View ArticlePubMedPubMed CentralGoogle Scholar
  40. Swarthout TD, Counihan H, Senga RK, van den Broek I: Paracheck-Pf accuracy and recently treated Plasmodium falciparum infections: is there a risk of over-diagnosis?. Malar J. 2007, 6: 58-10.1186/1475-2875-6-58.View ArticlePubMedPubMed CentralGoogle Scholar
  41. Siripoon N, Snounou G, Yamogkul P, Na-Bangchang K, Thaithong S: Cryptic Plasmodium falciparum parasites in clinical P. vivax blood samples from Thailand. Trans R Soc Trop Med Hyg. 2002, 96: 70-71. 10.1016/S0035-9203(02)90246-4.View ArticlePubMedGoogle Scholar
  42. Barber BE, William T, Grigg MJ, Parameswaran U, Piera KA, Price RN, Yeo TW, Anstey NM: Parasite Biomass-Related Inflammation, and Endothelial Activation, Microvascular Dysfunction and Disease Severity in Vivax Malaria. PLoS Pathogens, in Press 2014.Google Scholar

Copyright

© Douglas et al.; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.